BiotechTube
Theranano

Theranano

Houston, United States· Est.
theranano.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Theranano is a private, pre-revenue biotech company founded in 2015, advancing a pipeline of nanomedicine-based therapeutic and diagnostic platforms. Its lead programs include the InCeRT implant for localized cancer therapy, which is in IND-enabling studies, and the QUTE-CE MRI contrast agent, which is in a first-in-human clinical trial. The company leverages the scientific expertise of its founder, Dr. Srinivas Sridhar, and a team of domain experts in research, regulatory affairs, and manufacturing, with strategic access to Boston's medical research ecosystem.

Oncology

Technology Platform

Nanomedicine platforms for localized drug delivery (InCeRT implantable spacers) and quantitative diagnostic imaging (QUTE-CE MRI contrast agent using magnetic nanoparticles).

Opportunities

Theranano operates in the high-growth oncology market with technologies that address key limitations of current care: systemic toxicity of chemo and qualitative imaging.
Success could lead to partnerships with large pharma for late-stage development of its therapeutic programs or direct commercialization of its quantitative MRI agent, which meets the growing demand for precision diagnostics.

Risk Factors

The company faces high clinical development risk, as its novel nanomedicine platforms must prove safe and effective in human trials.
As a pre-revenue private company, it is heavily dependent on external funding, which may be difficult to secure.
It also operates in highly competitive and technically complex fields with significant regulatory hurdles.

Competitive Landscape

Theranano competes in the crowded nanomedicine and targeted drug delivery space against both large pharmaceutical companies and numerous biotech startups. Its QUTE-CE MRI agent faces competition from established contrast agent manufacturers and new entrants in quantitative imaging. Differentiation relies on demonstrating superior clinical utility and successful translation of its unique implant and nanoparticle formulations.

More companies in AI / Machine Learning →More companies in United States →